Hoping to skirt the slow pace of new drug development, researchers are leaning on AI to uncover fresh uses for known chemicals and already-approved treatments.
This is the second in a three-part series from Medscape Medical News on the impact of artificial intelligence on drug discovery and development.reports on AI's ability to create new proteins from scratch, streamlining the creation of protein-based therapeutics.
"Clinical trials with patient selection markers will dramatically improve success by up to 90%," Jun said. Available drugs only treat symptoms of CCM, such as seizures and bleeding in the brain. Cell imaging pointed to the effectiveness of a small molecule known as a superoxide scavenger. The researchers were surprised, but when they foundFor the approximately 350,000 people with CCM, a new treatment could become available soon. The finding may also have implications beyond CCM, which causes leaky blood vessels, a symptom seen in many other diseases, including multiple sclerosis and sepsis.
If compounds are well understood or have FDA approval for other indications, their toxicity and possible side effects have been assessed. Knowing that a drug can be safely administered to healthy patients"can save you the phase 1 trials," said Owen."Potentially, you can get into phase 2 trials, depending on the disease model evidence that you have."
Health And Medical Tech Health And Med Tech Health And Medical Technology Healthcare Technology Medical Technology Artificial Intelligence Deep Learning AI NPL Machine Learning ML Natural Language Processing Artificial Neural Networks Science And Innovations Genomics Genomic Medicine Rare Diseases Genetics Clinical Research Clinical Trials
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
AI's Drug Revolution, Part 1: Faster Trials and ApprovalsNew machine learning techniques plumb vast 'data lakes' to help researchers design faster, cheaper, more effective clinical trials — meaning accelerated approvals.
Read more »
US envoy defends anti-drug cooperation with Mexico amid neighbor's complaint on drug capo surrenderThe U.S. ambassador to Mexico is defending cross-border anti-drug cooperation after Mexican prosecutors complained the Americans aren't giving them enough information. Mexico's government was embarrassed by the surrender of two Mexican drug lords who arrived in Texas aboard a mysterious flight in July.
Read more »
UK drug regulator approves Alzheimer's drug but government likely won't pay for itBritain’s drug regulator has authorized the Alzheimer’s drug Leqembi, saying that it’s the first medicine to show some impact in slowing progression of the neurodegenerative disease. But the U.K.
Read more »
UK drug regulator approves Alzheimer's drug but government likely won't pay for itBritain’s drug regulator has authorized the Alzheimer’s drug Leqembi, saying that it’s the first medicine to show some impact in slowing progression of the neurodegenerative disease.
Read more »
UK drug regulator approves Alzheimer's drug but government likely won't pay for itBritain’s drug regulator has authorized the Alzheimer’s drug Leqembi, saying that it’s the first medicine to show some impact in slowing progression of the neurodegenerative disease.
Read more »
UK drug regulator approves Alzheimer's drug but government likely won't pay for itBritain’s drug regulator has authorized the Alzheimer’s drug Leqembi, saying that it’s the first medicine to show some impact in slowing progression of the neurodegenerative disease.
Read more »